Cortical alterations of peptidergic secretion in Alzheimer's disease = Alteraciones corticales de la secreción peptidérgica en la enfermedad de Alzheimer
[eng] The Alzheimer’s Disease (AD) is a neurodegenerative disease characterized by neurological alterations that lead to a severe cognitive decline and dementia. Nowadays has become the main cause of dementia, accounting for 50–70% of cases (Winblad et al., 2016). Commonly, the first symptom of the...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Estado: | Versión publicada |
| Fecha de publicación: | 2017 |
| País: | España |
| Institución: | Universidad de Barcelona |
| Repositorio: | Dipòsit Digital de la UB |
| OAI Identifier: | oai:diposit.ub.edu:2445/117968 |
| Acceso en línea: | https://hdl.handle.net/2445/117968 http://hdl.handle.net/10803/456816 |
| Access Level: | acceso abierto |
| Palabra clave: | Enfermedad de Alzheimer Escorça cerebral Neurotransmissió Alzheimer's disease Cerebral cortex Neural transmission |
| Sumario: | [eng] The Alzheimer’s Disease (AD) is a neurodegenerative disease characterized by neurological alterations that lead to a severe cognitive decline and dementia. Nowadays has become the main cause of dementia, accounting for 50–70% of cases (Winblad et al., 2016). Commonly, the first symptom of the dementia is the difficulty in the recall of recent events, which can progress rapidly into different personality and behavioral changes and a more severe impairment of the memory. Progressive advance of cognitive impairment interferes in the development of daily activities, causing a high grade of dependence, mainly in the final phases of the disease. (Winblad et al., 2016). As the prevalence of overall dementia rises steeply with age, being this factor the strongest risk factor for AD (American Psychiatric Association, 2013), the progressive aging of the population is increasing the incidence of the disease, which has become a global health problem. In fact, an estimated 40 million people, mostly older than 60 years, have dementia worldwide, and this number is estimated to double every 20 years, until at least 2050 (Qiu et al., 2009). This insidious onset and the gradual progression of impairment of AD –the average duration of illness is 8–10 years (Masters et al., 2015)- makes this pathology specially harmful compared to other diseases with a more clear clinical onset, and often abrupt resolution (Jack, 2012). Because of that, the disease has become an important economic charge for the health systems, which have to take care of a rising number of highly dependent people. |
|---|